Evidence map›Paper›PMID 31729775›Full record

ReviewDiabetic medicine : a journal of the British Diabetic Association2020

A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes.

S Bain, M Feher, M Fisher, N Hex, K C S Lee, J Mahon, D Russell-Jones, H Schou, E G Wilmot, M Baxter

Abstract readNetwork Meta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetic medicine : a journal of the British Diabetic Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Efficacy and Safety of Treatment with New Basal Insulin Analogues in Type 1 Diabetes: Nation-Wide Survey.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
    Article
  3. A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes.Diabetic medicine : a journal of the British Diabetic Association · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

S BainDiabetes Research Unit Cymru, University Medical School, Swansea, UK.ORCID 0000-0001-8519-4964
M FeherDepartment of Clinical and Experimental Medicine, University of Surrey, Guildford, UK.
M FisherDepartment of Diabetes, Endocrinology and Clinical Pharmacology, Glasgow Royal Infirmary, Glasgow, UK.
N HexYork Health Economics Consortium Ltd, University of York, York, UK.ORCID 0000-0002-6181-9429
K C S LeeSanofi, Paris, France.
J MahonYork Health Economics Consortium Ltd, University of York, York, UK.
D Russell-JonesDepartment of Diabetes and Endocrinology, Royal Surrey County Hospital and University of Surrey, Guildford, UK.
H SchouSanofi, Guildford, UK.
E G WilmotDepartment of Diabetes and Endocrinology, University Hospitals of Derby and Burton NHS FT, Derby, UK.ORCID 0000-0002-8698-6207
M BaxterSanofi, Guildford, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo revisit the data analysis used to inform National Institute of Health and Care Excellence (NICE) NG17 guidance for initiating basal insulin in adults with type 1 diabetes mellitus (diabetes).

methodsWe replicated the data, methodology and analysis used by NICE diabetes in the NG17 network meta-analysis (NMA). We expanded this data cohort to a more contemporary data set (extended 2017 NMA) and restricted the studies included to improve the robustness of the data set (restricted 2017 NMA) and in a post hoc analysis, changed the index comparator from neutral protamine Hagedorn (NPH) insulin twice daily to insulin detemir twice daily.

resultsThe absolute changes in HbA

conclusionsIn NG17, comparisons of basal insulins were based solely on efficacy of glycaemic control. Many of the trials used in this analysis were treat-to-target, which minimize differences in HbA

Indexed as

Diabetes Mellitus, Type 1Glycated HemoglobinHypoglycemic AgentsInsulinHumansHypoglycemiaInsulin DetemirInsulin GlargineInsulin, IsophaneInsulin, Long-ActingPractice Guidelines as TopicGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulininsulin degludecInsulin DetemirInsulin GlargineInsulin, IsophaneInsulin, Long-Acting

Identifiers

PMID31729775
PMCPMC7004078

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.